C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2026)

C4 Therapeutics' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $360000.0 for Q1 2026.

• On a quarterly basis, Depreciation and Depletion fell 1.1% year-over-year to $360000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 10.66% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 4.62% from the prior year.
• Depreciation and Depletion slipped to $360000.0 in Q1 2026 per CCCC's latest filing, from $377000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $545000.0 in Q1 2023 and bottomed at $128000.0 in Q4 2023.
• The 5-year median for Depreciation and Depletion is $377000.0 (2025), against an average of $385588.2.
• Across the five-year window, Depreciation and Depletion plunged 75.43% in 2023 and jumped 184.38% in 2024, its largest moves.
• Year by year, Depreciation and Depletion stood at $521000.0 in 2022, then plunged by 75.43% to $128000.0 in 2023, then soared by 184.38% to $364000.0 in 2024, then increased by 3.57% to $377000.0 in 2025, then slipped by 4.51% to $360000.0 in 2026.
• Per Business Quant, the three latest CCCC Depreciation and Depletion figures stand at $360000.0 (Q1 2026), $377000.0 (Q4 2025), and $384000.0 (Q3 2025).